PEB-Pacific Edge

[Greekwatchdog]

Posted om the other channel by Psychic

Veterans Drive Study published


https://scholar.google.co.nz/scholar...&pos=0&folt=kw

Extract from last PE update:
This publication provides the clinical validation evidence necessary for us to formally request our Medicare Administrative Contractor Novitas to consider coverage for Triage Plus

[Left Field]

Thanks GWD

This link may work better for some....

https://www.sciencedirect.com/science/article/pii/S1078143925004053

Onwards and upwards

[LoungeLizard]

The evidence has been overwhelmingly in favour of CXBladder for some time, and this is yet another validation. For whatever reason Novitas have done their utmost to ignore the evidence and expert opinion, but the game is up now. Shame we still have to wait until January for the meeting and then for whatever time they think they need to deliberate. Really, what is left to debate?

[Mad Goat Keeper]

The evidence has been overwhelmingly in favour of CXBladder for some time, and this is yet another validation. For whatever reason Novitas have done their utmost to ignore the evidence and expert opinion, but the game is up now. Shame we still have to wait until January for the meeting and then for whatever time they think they need to deliberate. Really, what is left to debate?

Cost... It's all about the bottom line. The test is too easy. A simple bio marker won't be as cost effective for Novitas as the current system is prohibitive.

[LoungeLizard]

Cost... It's all about the bottom line. The test is too easy. A simple bio marker won't be as cost effective for Novitas as the current system is prohibitive.

I don't get that - if it's easier then isn't it by default going to be cheaper?

Kaiser Permanente , the biggest non-profit health provider in the US - has been using CX Bladder for sometime, so there's a lot of data from them on the benefits of using CXBLadder. They estimate that they have cut the number of unnecessary cystoscopies by two thirds which apparently translates to a saving of US$560 per patient.
 
I think the delay in adoption is probably more to do with Medicare being notoriously slow to introduce new tests and even new drugs approved by the FDA. They've been criticised for this by a wide range of patient advocacy groups as well as the DOH itself.

[Pierre]

Cost... It's all about the bottom line. The test is too easy. A simple bio marker won't be as cost effective for Novitas as the current system is prohibitive.

Your comment makes no sense at all.
The PEB bio marker test WILL be cost-effective compared with cystoscopy.

[Greekwatchdog]

Your comment makes no sense at all.
The PEB bio marker test WILL be cost-effective compared with cystoscopy.

The test is much cheaper than a cystocopy, better for the patient and enviroment.

What PEB are dealing with is Amercian dumb arse. Remember 52% + voted for the most repulsive president on record.

[Mad Goat Keeper]

I don't get that - if it's easier then isn't it by default going to be cheaper?

Kaiser Permanente , the biggest non-profit health provider in the US - has been using CX Bladder for sometime, so there's a lot of data from them on the benefits of using CXBLadder. They estimate that they have cut the number of unnecessary cystoscopies by two thirds which apparently translates to a saving of US$560 per patient.
 
I think the delay in adoption is probably more to do with Medicare being notoriously slow to introduce new tests and even new drugs approved by the FDA. They've been criticised for this by a wide range of patient advocacy groups as well as the DOH itself.

Patients avoiding unnecessary cystoscopies is the ideal scenario so a saving would be expected. Those not so lucky would still require cystoscopies and the expensive bit, treatment...
It may well prove financially beneficial over time but you can guarantee this is numbers game and not an outcomes game.

[Left Field]

PEB playing soothing music while it places investors on hold......

Latest update....a test of investor patience.

https://api.nzx.com/public/announcement/463313/attachment/457570/463313-457570.pdf

[Greekwatchdog]

PEB playing soothing music while it places investors on hold......

Latest update....a test of investor patience.

https://api.nzx.com/public/announcement/463313/attachment/457570/463313-457570.pdf

As an investor I had no expectations on this result. Short term its all about news until issue with Novitas is resolved.

Listened to the meeting, CEO very confident on gaining coverage.
Possibly may need more cash in 9/12 months, who knows.

[LoungeLizard]

The Medicare decision is a make or break moment for PEB and investors. Should there be a favourable decision (highly likely) all numbers will instantly look good, particularly with the reimbursement rate being 75% higher and with the backlog of cases, currently not being funded, forming a large instant revenue boost.

I thought they would have enough funds to see them through the whole Novitas process, but maybe not.

These updates on where the business is now, without Medicare coverage, are largely irrelevent - it's all about a future where re-imbursement resumes. That future looks very, very good. It just needs to hurry up and arrive!

[Pierre]

The Medicare decision is a make or break moment for PEB and investors. Should there be a favourable decision (highly likely) all numbers will instantly look good, particularly with the reimbursement rate being 75% higher and with the backlog of cases, currently not being funded, forming a large instant revenue boost.

I thought they would have enough funds to see them through the whole Novitas process, but maybe not.

These updates on where the business is now, without Medicare coverage, are largely irrelevent - it's all about a future where re-imbursement resumes. That future looks very, very good. It just needs to hurry up and arrive!

Peter Meintjes is supremely confident of a positive outcome from Novitas. The question is when will the decision arrive - and Q3 or Q426 seems to be highly likely, but not guaranteed. Worst case is Q327.

Having sufficient cash until the result is known is the second issue. They were very cagey about that and how it would be dealt with, but indicated they may have some trick up their sleeve that would avoid them calling on shareholders for support.

I feel certain there will definitely be gold at the end of the rainbow. Patience grasshopper.

[Left Field]

Yes well said Pierre and LL..... my post earlier today was rather tongue in cheek....I'm used to being patient with PEB.

FWIW there was a really good interview this morning with Kathryn Ryan and RNZ's financial reporter who had spent some time reviewing ACC's investments and talking to one of their investment managers.

The upshot was that ACC likes having shareholdings in NZX small caps ( often too small to warrant the attention of brokers etc)  as although they are risky....it is where ACC makes its most impressive gains, (or words to that effect.)




 

[Shareguy]

Craigs latest say sell 9cps TP

Rob Morrison's Title for Pacific Edge "No longer flush with cash" clearly signals the looming issue for the company after yesterday's interim result. Morrison's extensive channel checks and clinical study deep dives indicate that Cxbladder delivers good clinical/economic value and should regain Medicare coverage by FY28 a view that is unchanged since 2023 and consistent with PEB's updated timeline released yesterday. However, in the interim, more cash is needed with PEB's cash balance at $22m (30 September) and a burn-rate of c$20m every 6 months on recent run-rates. Morrisons Target Price is unchanged at 9cps and with the shares now trading at 17cps his recommendation moves from Neutral to Underweight.

[LoungeLizard]

Craigs latest say sell 9cps TP

Rob Morrison's Title for Pacific Edge "No longer flush with cash" clearly signals the looming issue for the company after yesterday's interim result. Morrison's extensive channel checks and clinical study deep dives indicate that Cxbladder delivers good clinical/economic value and should regain Medicare coverage by FY28 a view that is unchanged since 2023 and consistent with PEB's updated timeline released yesterday. However, in the interim, more cash is needed with PEB's cash balance at $22m (30 September) and a burn-rate of c$20m every 6 months on recent run-rates. Morrisons Target Price is unchanged at 9cps and with the shares now trading at 17cps his recommendation moves from Neutral to Underweight.

Strange logic from Craigs, given that they accept that PEB "should regain" coverage yet have a target price of half the current price. Seems very short-sighted to value the company independent of regaining coverage, given how overwhelmingly positive the SP will respond when that happens.